GeneDx Holdings (WGS) Receivables (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables for 7 consecutive years, with $88.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 84.07% year-over-year to $88.4 million in Q2 2026; TTM through Jun 2026 was $88.4 million, a 84.07% increase from a year earlier, with the FY2025 full-year figure at $79.9 million, up 112.42% from the prior year.
• Receivables was $88.4 million for Q2 2026 at GeneDx Holdings, up from $81.7 million in the prior quarter.
• Over five years, Receivables peaked at $88.4 million in Q2 2026 and troughed at $28.2 million in Q1 2024.
• A 5-year average of $49.6 million and a median of $46.1 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 113.52% in 2022 and tumbled 31.04% in 2023, its largest moves.
• Over 5 years, Receivables stood at $44.1 million in 2022, then dropped by 26.6% to $32.4 million in 2023, then grew by 16.15% to $37.6 million in 2024, then surged by 112.42% to $79.9 million in 2025, then increased by 10.61% to $88.4 million in 2026.
• The last three Receivables figures came in at $88.4 million (Q2 2026), $81.7 million (Q1 2026), and $79.9 million (Q4 2025), per Business Quant data.